<DOC>
	<DOC>NCT01128569</DOC>
	<brief_summary>We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist (LABA)/ inhaled corticosteroid (ICS) combination product on protection from allergic triggers in asthma.</brief_summary>
	<brief_title>Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Body mass index within the range 18.535.0 kilograms/metre2 (kg/m2). Females of nonchild bearing potential. Documented history of bronchial asthma, first diagnosed at least 6 months prior to the screening visit and currently being treated only with intermittent shortacting beta agonist therapy by inhalation Prebronchodilator FEV1 &gt;70% of predicted at screening Subjects who are current nonsmokers Methacholine challenge PC20 &lt; 8 mg/mL at screening Screening allergen challenge demonstrates that the subject experiences an early asthmatic response Current or chronic history of liver disease, or known hepatic or biliary abnormalities Subject is hypertensive at screening Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the first dose of study medication. History of lifethreatening asthma Symptomatic with hay fever at screening or predicted to have symptomatic hayfever Unable to abstain from short acting beta agonists Unable to abstain from antihistamines Unable to abstain from other medications including nonsteroidal antiinflammatory drugs (NSAIDs), antidepressant drugs, antiasthma antirhinitis or hay fever medication The subject has participated in a study with a new molecular entity during the previous 3 months or has participated in 4 or more clinical studies in the previous 12 months undergoing allergen desensitisation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>mild asthma</keyword>
	<keyword>allergen challenge</keyword>
	<keyword>early asthmatic response</keyword>
</DOC>